诊断测试的在线图片研究:阿尔茨海默病诊断信心和耻辱的种族和种族差异
Shana D Stites1,2,3, Brian N Lee1, Carolyn Kuz1
1Department of Psychiatry, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
Alzheimer's & dementia (Amsterdam, Netherlands)
|October 10, 2025
概括
生物标志物测试,就像脑部扫描一样,可以提高跨种族群体的阿尔茨海默病 (AD) 诊断信心. 然而,没有一个小组获得了100%的信心,强调了需要改善以患者为中心的护理和平等获得诊断的需要.
科学领域:
- 神经学 神经学
- 医学诊断 医学诊断 医学诊断
- 健康差异 在健康上的差异
背景情况:
- 了解阿尔茨海默病 (AD) 诊断信心和跨种族群体的耻辱是早期干预的关键.
- 生物标志物测试对诊断信心和AD耻辱的影响需要进行调查.
研究的目的:
- 评估生物标志物测试如何影响多元种族和民族群体中AD诊断信心.
- 检查诊断评估,AD耻辱和诊断信心之间的关系.
主要方法:
- 成年人 (N=3548) 评估了使用临床图片的诊断场景和AD污名.
- 对收集的数据进行了双变量和多变量回归分析.
主要成果:
- 黑人参与者在包括脑部扫描时,诊断信心增长最少 (11.86分).
- 诊断信心因种族群体和诊断评估类型而异,受AD污名的影响.
结论:
- 脑部扫描可以提高AD诊断的信心普遍,但100%的信心仍然难以捉摸的所有群体.
- 以患者为中心的护理和系统变化是必要的,以改善诊断技术的获取和公平的护理.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.6K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
相关概念视频
Stereotypes, Prejudice, and Discrimination
94.9K
Humans are very diverse and although we share many similarities, we also have many differences. The social groups we belong to help form our identities (Tajfel, 1974). These differences may be difficult for some people to reconcile, which may lead to prejudice toward people who are different. Prejudice is a negative attitude and feeling toward an individual based solely on one’s membership in a particular social group (Allport, 1954; Brown, 2010). Prejudice is common against people who...
94.9K
Surveys
16.6K
Often, psychologists develop surveys as a means of gathering data. Surveys are lists of questions to be answered by research participants, and can be delivered as paper-and-pencil questionnaires, administered electronically, or conducted verbally. Generally, the survey itself can be completed in a short time, and the ease of administering a survey makes it easy to collect data from a large number of people.
16.6K
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia
517
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
517
